HPV legislation in Kansas

From SourceWatch
Jump to navigation Jump to search

Women in Government Ratings

Women in Government, a non-profit network of state level women legislators, receives significant funding from the pharmaceutical industry, including Merck, GlaxoSmithKline, and Digene Corporation -- all with products related to HPV vaccination and testing. According to their report, "The 'State' of Cervical Cancer Prevention in America - 2008" [1]:


POPULATION: 2,764,075


Incidence & Mortality (2008 Score / 2007 Score)

  • Cervical Cancer Incidence Rate: 7.9/100,000 (1/ 2)
  • Cervical Cancer Incidence Rate/Race: White: 7.5 , Black: 13.5, Hispanic: 12.1
  • Cervical Cancer Mortality Rate: 1.8/100,000 (2 / 1)
  • Cervical Cancer Mortality Rate/Race: White: 1.7 , Black: 4.0


Screening (2008 Score / 2007 Score)

  • Cervical Cancer Screening Rate: 83.4% (1 / 2)
  • Cervical Cancer Screening Rate/Race: White: 83.7%, Black: 87.1%, Hispanic: 83.5%
  • % Uninsured/Unscreened: 26.3% (1 / 1)
  • Medicaid Coverage HPV Testing: Unrestricted (2 / 2)


Healthcare Access (2008 Score / 2007 Score)

  • Rate Uninsured Women: 14% (1 / 1)
  • % Low Income/Uninsured Women: 31%


Policy Initiatives and Infrastructure (2008 Score / Cumulative Score (2005–2008)

Screening Requirements (0 / 1)

  • There are no new screening requirements.

Task Forces (0 / 1)

  • There is no new cervical cancer prevention task force legislation.

Access to HPV Vaccines (1 / 1)

  • HB 2227 would require girls entering the 6th grade to provide proof of receiving the HPV vaccine; allows for medical and religious exemptions; did not leave committee.

HPV Vaccine Information Programs (0 / 0)

  • There is no HPV vaccine information activity.

Miscellaneous (0 / 1)

  • There is no new miscellaneous cervical cancer prevention activity.


Annual Ratings

  • 2008: Good (12 out of 22 points)
  • 2007: Very Good (12 out of 18 points)


Articles and resources

SourceWatch Resources

External links

References